This section addresses hybridoma-based approaches to identifying antibody genes. Topics include common protocols, troubleshooting steps, and ongoing developments in sequencing.
Hybridoma technology, developed by Köhler and Milstein in 1975, introduced a method for the generation of monoclonal antibodies (mAbs) through the fusion of antigen-specific B lymphocytes with immortal myeloma cells. This approach enabled the long-term culture of hybrid cells—termed hybridomas—that produce highly specific antibodies targeting a single epitope.
Hybridoma sequencing secures valuable cell lines by capturing full antibody sequences with 100% accuracy. Biointron enables recombinant expression for reliable, consistent antibody production.
You can also contact us on the Scientist and Science Exchange marketplaces.
Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.
